Sanofi and Verily Launch Onduo

Article

The companies launched Onduo, a joint venture focused on developing solutions to assist patients with Type 2 diabetes.

Sanofi and Verily Life Sciences announced on Sept. 12, 2016 the launch of Onduo. Onduo, a joint venture created through Sanofi and Verily’s diabetes-focused collaboration, is designed to help patients with diabetes through the development of solutions that combine devices, software, medicine, and professional care. The companies appointed Joshua Riff, MD, MBA, Onduo’s chief executive officer, a former senior vice-president of UnitedHealth Group. “We want to develop solutions that allow people living with diabetes to focus on the things they love and enjoy in life by providing tools to make dealing with their diabetes less burdensome,” Riff said in a statement.

Onduo will initially focus on Type 2 diabetes, specifically focusing on improved medication management, and other daily decisions to help patients better manage their diabetes. Eventually Onduo says it will expand to include Type 1 diabetes and eventually, to people at risk of developing diabetes. Sutter Health of Northern California and Allegheny Health Network of western Pennsylvania are among the first healthcare networks to collaborate with Verily and Onduo to test the Onduo platform with healthcare professionals and people with Type 2 diabetes in a clinical-care setting.

Source: Sanofi

 

Recent Videos
Behind the Headlines episode 5
Pharm Tech Group looks at the challenges surrounding the development and manufacture of ATMPs in more detail with Agne Vaitkeviciene, CEO of Memel Biotech.
Pharm Tech Group sits down with Bernard Sagaert, CEO of etherna, to examine the role of mRNA in the treatment of autoimmune diseases.
Pharm Tech Group chats with Dr. Monika Paulė, CEO and co-founder of Caszyme about the evolution of CRISPR.
Related Content
© 2024 MJH Life Sciences

All rights reserved.